These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 34158843)

  • 1.
    Shi Z; Shen J; Qiu J; Zhao Q; Hua K; Wang H
    Theranostics; 2021; 11(15):7175-7187. PubMed ID: 34158843
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of immunotherapy biomarkers for improving the clinical outcome of homologous recombination deficiency patients with lung adenocarcinoma.
    Zhou X; Xu R; Lu T; Xu R; Wang C; Peng B; Chang X; Shen Z; Wang K; Shi J; Zhao J; Zhang LY
    Aging (Albany NY); 2023 Aug; 15(16):8090-8112. PubMed ID: 37578930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders.
    Yang C; Zhang Z; Tang X; Zhang X; Chen Y; Hu T; Zhang H; Guan M; Zhang X; Wu Z
    Hum Cell; 2022 Jan; 35(1):199-213. PubMed ID: 34628623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma.
    Shi Z; Zhao Q; Lv B; Qu X; Han X; Wang H; Qiu J; Hua K
    Clin Transl Med; 2021 May; 11(5):e399. PubMed ID: 34047476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of CXCL13 as a Promising Biomarker for Immune Checkpoint Blockade Therapy and PARP Inhibitor Therapy in Ovarian Cancer.
    Ding Y; Ye Z; Ding B; Feng S; Zhang Y; Shen Y
    Mol Biotechnol; 2024 Jun; ():. PubMed ID: 38856873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCL10 and CCL5 as feasible biomarkers for immunotherapy of homologous recombination deficient ovarian cancer.
    Han Y; Guo Z; Jiang L; Li X; Chen J; Ouyang L; Li Y; Wang X
    Am J Cancer Res; 2023; 13(5):1904-1922. PubMed ID: 37293164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homologous recombination deficiency in triple-negative breast cancer: Multi-scale transcriptomics reveals distinct tumor microenvironments and limitations in predicting immunotherapy response.
    Kang K; Wu Y; Han C; Wang L; Wang Z; Zhao A
    Comput Biol Med; 2023 May; 158():106836. PubMed ID: 37031511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types.
    Budczies J; Kluck K; Beck S; Ourailidis I; Allgäuer M; Menzel M; Kazdal D; Perkhofer L; Kleger A; Schirmacher P; Seufferlein T; Stenzinger A
    J Pathol Clin Res; 2022 Jul; 8(4):371-382. PubMed ID: 35384413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer.
    Liao G; Jiang Z; Yang Y; Zhang C; Jiang M; Zhu J; Xu L; Xie A; Yan M; Zhang Y; Xiao Y; Li X
    BMC Med; 2021 Sep; 19(1):190. PubMed ID: 34465315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer.
    Qiu P; Guo Q; Yao Q; Chen J; Lin J
    Front Immunol; 2021; 12():736030. PubMed ID: 34659224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients.
    Chen Y; Zheng X; Lin J; Gao X; Xiong J; Liu J; Fei Z; Chen C
    Oral Oncol; 2022 May; 128():105860. PubMed ID: 35428026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
    Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
    BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of HRD functional phenotype impedes immunotherapy and can be reversed by HDAC inhibitor in ovarian cancer.
    Yang D; Huang FX; Wei W; Li QQ; Wu JW; Huang Y; Li ZL; Zhang HL; Li X; Yuan QE; Chen QS; Feng GK; Rong D; Li JD; Zhu XF
    Int J Biol Sci; 2023; 19(6):1846-1860. PubMed ID: 37063431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors.
    Kim H; Ahn S; Kim H; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim KM; Kim ST
    J Cancer Res Clin Oncol; 2022 Sep; 148(9):2427-2435. PubMed ID: 34510272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
    Ueno T; Kitano S; Masuda N; Ikarashi D; Yamashita M; Chiba T; Kadoya T; Bando H; Yamanaka T; Ohtani S; Nagai S; Nakayama T; Takahashi M; Saji S; Aogi K; Velaga R; Kawaguchi K; Morita S; Haga H; Ohno S; Toi M
    BMC Med; 2022 Apr; 20(1):136. PubMed ID: 35462552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
    Imanishi S; Naoi Y; Shimazu K; Shimoda M; Kagara N; Tanei T; Miyake T; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2019 Apr; 174(3):627-637. PubMed ID: 30607631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Features of Homologous Recombination Deficiency in Breast Cancer: Impact on Testing and Immunotherapy.
    Ali U; Vungarala S; Tiriveedhi V
    Genes (Basel); 2024 Jan; 15(2):. PubMed ID: 38397152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic and molecular landscape of homologous recombination deficiency across multiple cancer types.
    Shi Z; Chen B; Han X; Gu W; Liang S; Wu L
    Sci Rep; 2023 Jun; 13(1):8899. PubMed ID: 37264024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer.
    Kraya AA; Maxwell KN; Wubbenhorst B; Wenz BM; Pluta J; Rech AJ; Dorfman LM; Lunceford N; Barrett A; Mitra N; Morrissette JJD; Feldman M; Nayak A; Domchek SM; Vonderheide RH; Nathanson KL
    Clin Cancer Res; 2019 Jul; 25(14):4363-4374. PubMed ID: 30914433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.